BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary pancreatic cancer.
Diskin B, Adam S, Soto GS, Liria M, Aykut B, Sundberg B, Li E, Leinwand J, Chen R, Kim M, Salas RD, Cassini MF, Buttar C, Wang W, Farooq MS, Shadaloey SAA, Werba G, Fnu A, Yang F, Hirsch C, Glinski J, Panjwani A, Weitzner Y, Cohen D, Asghar U, Miller G.
Diskin B, et al.
Oncogene. 2022 Sep;41(38):4349-4360. doi: 10.1038/s41388-022-02425-4. Epub 2022 Aug 10.
Oncogene. 2022.
PMID: 35948648